Compare ArcelorMittal SA (MT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs Recursion Pharmaceuticals Inc — how do they compare? ArcelorMittal SA trades at $64.02 (market cap $45.70B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B). The key difference: ArcelorMittal SA is far larger — about 21.4× Recursion Pharmaceuticals Inc's market cap, and ArcelorMittal SA pays a 0.98% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ArcelorMittal SA for 36 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MT | RXRX | |
|---|---|---|
Market Cap | $45.70B | $2.14B |
Volume | 1,964,621 | 30,789,535 |
Sector | Basic Materials | Health |
52-Week High | $78.74 | $6.79 |
52-Week Low | $36.91 | $2.84 |
Typical Hold Time | 36 Days | 22 Days |
Enterprise Value | $55.27B | $1.66B |
Dividend Yield | 0.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $62.32, down 4.4% today, with technical indicators signaling bearish momentum. The stock shows mixed fundamentals with revenue declining from $79.8B in 2022 to $61.4B in 2025, though net income improved to $3.2B. Recent news highlights operational disruptions at its Ukrainian plant with a potential $1B impairment charge, while analyst consensus remains positive with a $74.33 price target.
The outlook is cautious due to geopolitical risks and declining revenue trends, but valuation metrics appear reasonable with P/E of 26.2 and P/B of 0.86. Investment opportunity exists if European operations stabilize and growth projects deliver, though investors face headwinds from steel demand volatility and ongoing Ukraine-related impairments.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
